Estimating Long-Term PFS and OS in Patients with PTCL: A US Population-Based OSM Using 5-Year Results From the ECHELON-2 Trial

As the US population ages, more patients are anticipated to be diagnosed with peripheral T-cell lymphoma (PTCL). Using a mathematical model and clinical trial data, Curta investigators estimated for the year 2031 the effect of using A+CHP (brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) as frontline treatment of PTCL. Results show that increasing use of frontline A+CHP vs CHOP leads to more patients with PTCL alive and without disease progression in 2031.

To access the full publication, visit:
https://pubmed.ncbi.nlm.nih.gov/36840956/